Thursday 16 October, 2025
Objectives: In metastatic cancer, the growth and drug-induced shrinkage of individual tumor lesions may be highly dependent on the microenvironment…
Read morePoster: Drug/Disease Modelling - Oncology
Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer
Thursday 16 October, 2025
Introduction: Tumor size, quantified by the Sum of Longest Diameters of target lesions (SLD), has been established as a prognostic…
Read morePharmacometric Analysis in Support of Dose Optimization for Pemigatinib Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangements
Thursday 16 October, 2025
Objectives: The objectives were to characterize the pemigatinib pharmacokinetics (PK) and exposure-response (E-R) relationships to support the dose recommendation for…
Read moreModelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice
Thursday 16 October, 2025
Objectives: Oncogenic rearrangements of neurotrophic tyrosine receptor kinase (NTRK) encode chimeric proteins with constitutive kinase activity, which promote tumour cell…
Read morePopulation modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor
Thursday 16 October, 2025
Introduction: Tumor growth curves are classically modeled by ordinary differential equations. In analyzing the Gompertz model several studies have reported…
Read moreMechanistic models of cancer-immune cycle and immunotherapies
Thursday 16 October, 2025
Introduction: Immuno-oncology (IO), where treatments mobilize a patient’s immune system to fight cancer and provide lasting therapeutic benefit, is the…
Read moreExplaining inter-species differences to anti-PDL1 cancer immunotherapy using a translational quantitative systems pharmacology approach
Thursday 16 October, 2025
Objectives: Tumor cells can exploit host immune checkpoints to allow them to evade eradication by the immune system. For several…
Read morePopulation pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example
Thursday 16 October, 2025
Introduction: Ewing sarcoma is a very aggressive bone tumour, which often occurs in adolescents or young adulthood [1]. The incidence…
Read moreModelling approaches to support tusamitamab ravtansine (DM4 anti-CEACAM5 antibody-drug conjugate) drug development.
Thursday 16 October, 2025
Objectives: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell-surface glycoprotein highly expressed in several tumor types. Tusamitamab ravtansine…
Read moreIntegrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
Thursday 16 October, 2025
Introduction: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell-surface glycoprotein highly expressed in several tumor types [1]. Tusamitamab…
Read more